Sarepta Therapeutics (SRPT) Work In Process (2022 - 2026)

Sarepta Therapeutics' Work In Process history runs 5 years deep, the most recent figure standing at $981.0 million for Q1 2026.

• On a quarterly basis, Work In Process rose 28.71% year-over-year to $981.0 million in Q1 2026; TTM through Mar 2026 was $981.0 million, a 28.71% increase from a year earlier, with the FY2025 full-year figure at $892.7 million, up 46.18% from the prior year.
• Work In Process improved to $981.0 million in Q1 2026 per SRPT's latest filing, from $892.7 million in the prior quarter.
• Across five years, Work In Process topped out at $981.0 million in Q1 2026 and bottomed at $269.2 million in Q4 2022.
• The 5-year median for Work In Process is $686.5 million (2024), against an average of $647.5 million.
• Across the five-year window, Work In Process advanced 18.3% in 2023 and jumped 91.77% in 2024, its largest moves.
• Year by year, Work In Process stood at $269.2 million in 2022, then advanced by 18.3% to $318.5 million in 2023, then soared by 91.77% to $610.7 million in 2024, then surged by 46.18% to $892.7 million in 2025, then gained by 9.9% to $981.0 million in 2026.
• Per Business Quant, the three latest SRPT Work In Process figures stand at $981.0 million (Q1 2026), $892.7 million (Q4 2025), and $885.4 million (Q3 2025).